Semaglutide weight plateau: when and what to do
The semaglutide weight curve plateaus earlier than tirzepatide, typically around month 6-9 at maintenance dose. The management mirrors the tirzepatide approach.
The mechanism
Semaglutide produces less peak weight loss than tirzepatide (15% in STEP-1 vs 22.5% in SURMOUNT-1) and reaches its plateau earlier. The mechanism is the same: the body finding a new metabolic equilibrium at the lower weight, where continuing to lose requires either more drug effect (up to the maintenance dose ceiling) or more behavioral effort.
What to expect
Most patients on semaglutide reach 12-15% weight loss by month 6-9 and plateau there. Some reach 18%+ at full 2.4mg dose; some plateau earlier at 8-10%. The variance is genetic, behavioral, and metabolic.
Management
Audit calories. Audit training (resistance training matters more than cardio at the plateau). Audit sleep + stress. If all three are clean and you're plateaued at month 9 on 2.4mg, the plateau may be the new equilibrium. Switching to tirzepatide produces additional 5-10% loss for most patients (the GIP arm adds incremental efficacy), which is the strongest argument for the switch.
When to escalate
Plateau accompanied by weight regain warrants investigation of underlying cause. Plateau accompanied by new symptoms warrants a basic workup. The switch-to-tirzepatide conversation is appropriate at month 9-12 if you've maxed semaglutide and want more loss.
- STEP-1 (Wilding et al., NEJM 2021)
- STEP-4 (Rubino et al., JAMA 2021)